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SIC and DRS are related proteins present in only 4 of the>200 Streptococcus pyogenes emm types. These proteins inhibit com-
plement-mediated lysis and/or the activity of certain antimicrobial peptides (AMPs). A gene encoding a homologue of these pro-
teins, herein called DrsG, has been identified in the related bacterium Streptococcus dysgalactiae subsp. equisimilis. Here we
show that geographically dispersed isolates representing 14 of 50 emm types examined possess variants of drsG. However, not all
isolates within the drsG-positive emm types possess the gene. Sequence comparisons also revealed a high degree of conservation
in different S. dysgalactiae subsp. equisimilis emm types. To examine the biological activity of DrsG, recombinant versions of
twomajor DrsG variants, DrsGS and DrsGL, were expressed and purified.Western blot analysis using antisera raised to these
proteins demonstrated both variants to be expressed and secreted into culture supernatants. Unlike SIC, but similar to DRS,
DrsG does not inhibit complement-mediated lysis. However, like both SIC and DRS, DrsG is a ligand of the cathelicidin LL-37
and is inhibitory to its bactericidal activity in in vitro assays. Conservation of prolines in the C-terminal region also suggests that
these residues are important in the biology of this family of proteins. This is the first report demonstrating the activity of an
AMP-inhibitory protein in S. dysgalactiae subsp. equisimilis and suggests that inhibition of AMP activity is the primary function
of this family of proteins. The acquisition of the complement-inhibitory activity of SICmay reflect its continuing evolution.
Antimicrobial peptides (AMPs) are major components of theinnate immune system that typically exert their antimicrobial
activity via pore formation in the bacterial membrane (1). Some
AMPs are also reported to have chemotactic properties, recruiting
immune cells such as monocytes, neutrophils, and T cells to the
site of bacterial colonization (2), or to directly stimulate chemo-
kine or cytokine secretion (3). Active evasion or inhibition of
AMP activity is therefore a strategy for the survival and multipli-
cation of several pathogens that colonize the respiratory tract and
skin (4).
Streptococcus pyogenes (group A streptococcus [GAS]) and S.
dysgalactiae subspecies equisimilis (human group C and G strep-
tococci) are related Gram-positive bacteria that colonize the skin
and throat. While S. pyogenes is generally considered to be more
virulent, the range of disease associated with S. dysgalactiae subsp.
equisimilis is similar to that for GAS (5, 6). There is also evidence of
increasing pathogenesis within the S. dysgalactiae subsp. equisi-
milis population (7–9). Both organisms must contend with the
innate immune system at the colonization sites. Some strains of S.
pyogenes express related secretory proteins, called SIC and DRS.
SIC is found in only two S. pyogenes emm types, emm1 and
emm57, and was first reported as a ligand for the complement
proteins C6 and C7, inhibiting the formation of the membrane
attack complex, thereby blocking complement-mediated lysis (10,
11). SIC was subsequently shown to inhibit the antimicrobial ac-
tivity of numerous AMPs and proteins, including LL-37, ly-
sozyme, secretory leukocyte proteinase inhibitor (SLPI), and hu-
man  and  defensins (12, 13). Additionally, SIC is inhibitory to
the antimicrobial activity of several chemokines which are se-
creted on the pharyngeal epithelial surface (14). DRS is a variant of
SIC present in emm12 and emm55 GAS (15). The greatest homol-
ogy between the two proteins is found in their proline-rich region
(PRR) (16). While DRS is a ligand of C6 and C7, this binding does
not inhibit complement function (15). DRS-SLPI interactions
also do not prevent SLPI from killing M12 GAS. However, DRS
binding to human  defensin 2 (hD-2), hD-3, and LL-37 ab-
rogates their antibacterial activity (17).
DNA encoding an orthologue of the SIC gene, previously
called sicG, has been described for S. dysgalactiae subsp. equisimilis
(18). Indeed, microarray screening of several S. dysgalactiae subsp.
equisimilis strains revealed the possible presence of a sic-like gene
in some isolates (19). However, as the similarity between SicG and
DRS is more pronounced than that between SicG and SIC, for this
report we renamed the protein and its gene DrsG and drsG, re-
spectively. Here we report that DrsG is a highly conserved secre-
tory protein, with variation occurring principally due to the pres-
ence of one or more repeat domains. DrsG does not inhibit
complement-mediated lysis of sheep red blood cells. However,
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DrsG does bind to LL-37, thereby inhibiting its bactericidal activ-
ity. The fact that DrsG, DRS, and SIC all have LL-37-inhibitory
activity suggests that this is the primary function of this family of
proteins. Finally, we show that many S. dysgalactiae subsp. equisi-
milis emm types contain isolates that harbor drsG. Unlike in GAS,
not all isolates in these S. dysgalactiae subsp. equisimilis emm types
possess drsG. The highly conserved nature of DrsG and its incon-
sistent distribution within isolates of an emm type suggest prolific
acquisition of the gene through lateral gene transfers (LGT) in S.
dysgalactiae subsp. equisimilis lineages.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The clinical isolates S. dysgalac-
tiae subsp. equisimilis MD128 (stg93464), MD985 (stc1400), MD604
(stc1400), MD03 (stg2078), and GGS124 (stg480) were described previ-
ously (19, 20). An additional 188 S. dysgalactiae subsp. equisimilis isolates,
collected primarily from Australia (n  89), the United States (n  66),
Japan (n 6), Portugal (n 12), and India (n 14) and representing 50
emm types, were used to examine the distribution of drsG (21–25). Unless
otherwise specified, S. dysgalactiae subsp. equisimilis and S. pyogenes were
grown in Todd-Hewitt broth (THB), Todd-Hewitt agar (Oxoid), or Co-
lumbia agar (CBA; Oxoid) supplemented with 5% defibrinated horse
blood. Escherichia coli was grown on LB medium supplemented with am-
picillin (100 g ml1) where appropriate.
Detection of drsG in S. dysgalactiae subsp. equisimilis. The presence
of drsG in the genomes of multiple S. dysgalactiae subsp. equisimilis iso-
lates was determined using a combination of PCR, Southern hybridiza-
tion, and interrogation of draft S. dysgalactiae subsp. equisimilis genome
sequences by BLASTn. PCR was performed using GoTaq Green master
mix (Promega) following the manufacturer’s recommendations. The
Sicn2F (5=-GGAGGTCACAAACTAAGCAA-3=) and Sicc3R (5=-TGCCT
ATAGAAGGCACAACT-3=) primer sequences are located upstream and
downstream of drsG, respectively. The Sicn1F (5=-AGTAAAACACTACT
ATTTACA-3=) and Sicc1R (5=-AGTCATATGGCCAATCTT-3=) primer
sequences are complementary to internal drsG sequences (20). For South-
ern hybridization, genomic DNA was digested to completion at 37°C for 3
h with KpnI (New England BioLabs), electrophoresed in a 0.8% agarose
gel, transferred to a nylon membrane (Amersham Biosciences), and
probed with a digoxigenin (DIG)-dUTP-labeled internal 250-bp frag-
ment of drsG. Following hybridization, the membranes were washed,
blocked, and incubated with anti-DIG alkaline phosphatase-conjugated
antibody (Roche Diagnostics) (1:20,000) prior to immunodetection with
CDP-Star detection reagent (Tropix) and development (26).
Bioinformatic analyses. Repeat sequences were identified using
RADAR (27, 28). Pairwise and multiple-sequence alignments were con-
ducted using NEEDLE and Clustal Omega (29), respectively. Putative
signal sequences were detected using SignalP (30).
Detection of DrsG in culture supernatants. Two milliliters of 100%
trichloroacetic acid (TCA) was added to 20-ml overnight cultures of S.
dysgalactiae subsp. equisimilis and left on ice for 30 min. The precipitated
proteins were collected by centrifugation (10,000 g for 5 min), washed
in 10% TCA, and dissolved in 250 l of 0.1 N NaOH. The total protein
concentration was determined using a bicinchoninic acid (BCA) protein
assay (Thermo Scientific). An aliquot of the protein solution was electro-
phoresed in an SDS-PAGE gel, transferred to nitrocellulose, and probed
with murine anti-DrsGL or -DrsGS antiserum followed by secondary goat
anti-mouse IgG conjugated to horseradish peroxidase (HRP). The mem-
branes were then immersed in ECL Plus chemiluminescence substrate
(Amersham Biosciences) and exposed to X-ray film.
Protein expression and production of antisera. Codon-optimized
DNAs encoding mature DrsGS and DrsGL were cloned into the expres-
sion vector pJ404 by DNA2.0 (Menlo Park, CA). The resulting plasmids
were transformed into E. coli Top10 cells, and recombinant protein ex-
pression was induced by the addition of 1 mM IPTG (isopropyl--D-
thiogalactopyranoside) to the mid-log-phase cultures. After a 3-h incuba-
tion, the pellets were lysed under native, nondenaturing conditions.
Recombinant DrsG proteins were then purified using His-Trap HP 1-ml
columns (GE Healthcare Life Sciences). Antibodies to the two DrsG vari-
ants were produced in Quackenbush mice by immunization with the pro-
teins emulsified in complete Freund’s adjuvant, followed by boosts with-
out adjuvant on days 21 and 28 (31). Recombinant SIC from M1 GAS was
expressed and purified as previously described (32). The use of mice in
this project was approved by the QIMR Animal Ethics Committee.
Complement-mediated lysis. Complement-mediated lysis of sheep
erythrocytes was performed as previously described (15). Briefly, sheep
erythrocytes (Applied Biological Products Management) were sensitized
with hemolysin (Virion) in gelatin Veronal buffer (GVB) for 30 min
at 37°C, followed by 30 min on ice. Human serum from human male AB
plasma (Sigma-Aldrich), used as the complement source in these experi-
ments, was titrated with sensitized sheep erythrocytes to determine the
dilution that caused approximately 50% hemolysis of sheep erythrocytes.
For the assay, 200 pmol of recombinant protein (DrsGS, DrsGL, or SIC)
or phosphate-buffered saline (PBS) was preincubated with diluted human
serum that resulted in 50% hemolysis for 10 min at 37°C. Hemolysin-
activated sheep erythrocytes (2.5  107 cells/well) were then added and
incubated at 37°C for a further 15 min. Unlysed erythrocytes were re-
moved by centrifugation at 400 g for 10 min, and hemolysis was mea-
sured by reading the absorbance of the supernatant at 415 nm. Lysis of
sheep erythrocytes with water was considered 100% lysis. Statistical sig-
nificance was determined using the unpaired t test.
LL-37 binding to DrsG. Microtiter plates (LinBro polyvinyl chloride
enzyme immunoassay plates; MP Biomedicals) were coated with 100l of
coating buffer (50 mM carbonate coating buffer, pH 9.6) containing 10g
of DrsG or SIC, in triplicate. The plates were incubated overnight at 4°C,
washed once with PBS-Tween 20 (PBST), and then blocked with PBST
containing 5% skim milk powder for 1 h at 37°C. Plates were washed once
using PBST and incubated (1 h at 37°C) with 10g of LL-37 (Peptide 2.0,
Chantilly, VA) in 0.5% skim milk-PBST buffer. After washing, the bind-
ing of LL-37 was detected with primary rabbit anti-LL-37 IgG (1:5,000;
Osenses) and horseradish peroxidase-labeled goat anti-rabbit secondary
IgG (1:5,000; Sigma). Wells in which LL-37, primary antibody, or second-
ary antibody was omitted were used as controls. Reciprocal assays, in
which LL-37 was used as the bound substrate and free recombinant DrsG
or recombinant SIC was added, were also performed.
LL-37 survival assays. Survival assays were performed to assess the
capacity of DrsG to inhibit LL-37-mediated killing of S. dysgalactiae
subsp. equisimilis MD985 (drsG negative). For these experiments, 25 M
LL-37 was preincubated with 25 M DrsG or SIC for 30 min at 37°C in
PBS. Mid-log-phase S. dysgalactiae subsp. equisimilis MD985 was har-
vested and diluted to an optical density at 600 nm (OD600) of 0.1. Ten
microliters of the LL-37–protein mix was then added to 90 l of the
bacterial culture and incubated at 37°C for a further 2.5 h. Serially diluted
mixes were plated in duplicate onto Todd-Hewitt agar and incubated
overnight. The percentage of CFU recovered was determined by compar-
ing recovery in the absence and presence of LL-37. Data presented are
means for three independent experiments, each performed in duplicate.
RESULTS
Distribution and conservation of drsG in S. dysgalactiae subsp.
equisimilis. PCR (Fig. 1), Southern hybridization (Fig. 2), and
examination of draft S. dysgalactiae subsp. equisimilis genome se-
quences resulted in identification of drsG in 30 of 193 S. dysgalac-
tiae subsp. equisimilis isolates (Table 1). Analysis of these se-
quences revealed the presence of two major variants. DrsGL
(DrsG-large) is a 25-kDa protein that contains a putative signal
sequence and two repeat domains. The first repeat domain (RD1)
comprises two repeat units, each of which also contains shorter
internal repeat sequences (Fig. 3). The second repeat domain
(RD2) includes two 12-amino-acid repeating units separated by a
Smyth et al.
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spacer sequence. In contrast, DrsGS (i.e., DrsG-small) lacks one of
the repeat units in RD1, plus the amino acids between the first two
repeat units. Otherwise, DrsGS is 100% identical to DrsGL at the
amino acid level. In total, 23 isolates possessed drsGS, and 7 pos-
sessed drsGL. Of the 50 emm types examined, 14 contained isolates
that were drsG positive (Table 2). However, for some emm types
represented by multiple isolates, not all isolates within these emm
types possessed drsG. Isolates of emm types stc839, stc1400, and
stg480 may contain either of these variants.
Similarity between DrsG, DRS, and SIC. DRS and SIC from
GAS possess a signal sequence, a short repeat region (SRR), a
proline-rich region (PRR), and a C-terminal domain (C-term).
SIC additionally possesses a long repeat region (LRR). To identify
the regions of identity between these proteins and DrsGS from S.
dysgalactiae subsp. equisimilis, pairwise alignments using full-
length proteins were performed. Relatively low overall sequence
identities of 34% and 22% were observed in comparing DrsGS
with DRS from GAS NS488 and with SIC from GAS AP1, respec-
tively, with the greatest identity in the signal sequence. When only
amino acid-represented overlapping sequences for the mature
proteins were used, the identities increased to 42% and 33%, re-
spectively. On the basis of these observations, we use the termi-
nology DrsG to describe this protein of S. dysgalactiae subsp. eq-
uisimilis. Similar to DRS and SIC, the C-terminal region of DrsG
contains an overrepresentation of proline residues.
DrsG is a secretory protein.DRS and SIC in GAS are secretory
products. Since DrsGS and DrsGL possess similar signal se-
quences, we predicted that they would also be secreted by S. dys-
galactiae subsp. equisimilis isolates positive for these genes. This
was confirmed by Western blotting of TCA-precipitated culture
supernatants from both stationary- and log-phase S. dysgalactiae
subsp. equisimilis cultures (Fig. 4). After probing with DrsGL and
DrsGS antibodies, bands at	27 kDa and	24 kDa were observed
in the culture supernatants of GGS124 (drsGL positive) and
MD604 (drsGS positive), respectively, but were absent in those of
the drsG-negative isolates, MD985 and MD128.
DrsG does not inhibit complement-mediated lysis. DRS and
SIC are known to bind to complement proteins, but only SIC
inhibits complement-mediated lysis. We therefore examined
FIG 1 PCR detection of drsG in S. dysgalactiae subsp. equisimilis. Representa-
tive gels demonstrate amplification of drsG from S. dysgalactiae subsp. equisi-
milis chromosomal DNA by use of internal (A) and external (B) primer sets.
Markers (kb) are shown to the left of the gels. Isolates and their respective emm
types are shown at the top of the figure.
FIG2 Chromosomal detection of drsG in S. dysgalactiae subsp. equisimilis and
GAS. KpnI-digested chromosomal DNAs from five S. dysgalactiae subsp. eq-
uisimilis isolates (MD10, ES61, TK01, MD128, and MD03) and two GAS iso-
lates (M12 and M1) were probed with a DIG-dUTP-labeled internal 250-bp
fragment of drsG. The emm type of each strain is also shown at the top of the
figure. Positive bands at 4.3 kb were detected for MD10, TK01, and MD03, but
not the other strains. Molecular size markers are shown to the left of the figure.
TABLE 1 drsG-positive isolates are geographically distributed
Strain emm type Geographical origin drsG variant
NS4186 stc6979 Australia drsGS
NS4760 stc6979 Australia drsGS
NS3874 stc74a Australia drsGS
MR363962 stg2078 Portugal drsGS
MR394314 stg2078 Portugal drsGS
TK01 stg2078 Japan drsGS
NCU133 stg2078 Japan drsGS
6458-05 stg2078 USA drsGS
3993-06 stg2078 USA drsGS
3537-05 stg2078 USA drsGS
MD03 stg2078 Australia drsGS
GCS11ny stc839 India drsGL
MR223754 stc839 Portugal drsGL
MD504 stc839 Australia drsGS
NS3975 stc839 Australia drsGS
NS4722 stc839 Australia drsGS
NS4599 stc839 Australia drsGS
3878–06 emm57 USA drsGL
8139–05 emm57 USA drsGL
NCU21 stg62647 Japan drsGS
GGS124 stg480 Japan drsGL
KTS-1 stg480 Japan drsGS
81-4 stg643 Japan drsGS
6037-03 stg245 USA drsGS
3442-04 stg3442 USA drsGS
3122-05 stg485 USA drsGS
3836-05 stg5063 USA drsGL
8983-04 stc1400 USA drsGL
MD604 stg6 Australia drsGS
MD10 stg1400 Australia drsGS
Characterization of drsG
June 2014 Volume 82 Number 6 iai.asm.org 2339
 o
n
 O
ctober 20, 2015 by University of Queensland Library
http://iai.asm
.org/
D
ow
nloaded from
 
whether DrsGS and DrsGL had any inhibitory effect on comple-
ment function. To do so, sheep erythrocytes sensitized with he-
molysin were incubated with equimolar concentrations of the re-
combinant proteins and with human serum as a source of
complement. Recombinant SIC showed significant inhibition of
lysis of erythrocytes (37.3% 
 1.5%; P  0.0005) compared to
PBS controls (no inhibition). However, neither DrsGL nor DrsGS
showed inhibitory activity (Fig. 5).
DrsG is a ligand of LL-37. Indirect enzyme-linked immu-
nosorbent assays (ELISAs) were used to determine whether LL-37
was a ligand of DrsGS and DrsGL. Wells coated with the recom-
binant proteins reacted with LL-37, and the binding was detected
with anti-LL-37 antibodies and labeled secondary antibody. Com-
pared to the negative controls, which lacked individual assay com-
ponents, the optical densities observed in experimental wells were
significantly greater (Fig. 6). In fact, binding between LL-37 and
DrsGS was the same as that observed for LL-37 and SIC. However,
when the reciprocal assays were performed, with LL-37 bound to
the plate and free DrsG and anti-DrsG antibodies used, no binding
between DrsG and LL-37 was observed. This equivocal result on
physical binding required further experiments using biological
activity, as described below.
Addition of DrsG increases the viability of S. dysgalactiae
subsp. equisimilis in the presence of LL-37. To investigate
whether the interactions between DrsG and LL-37 observed above
inhibited the bactericidal activity of LL-37, S. dysgalactiae subsp.
equisimilis MD985 (drsG negative) was incubated in the presence
of LL-37, DrsG, or LL-37 preincubated with DrsG (Fig. 7). LL-37
inhibited the growth of MD985 by 61% compared to controls.
Preincubation of LL-37 with DrsGL, DrsGS, or SIC restored
growth to 80% or more. These results suggest that DrsG is capable
of inhibiting the bactericidal activity of LL-37.
DISCUSSION
LL-37 is an important AMP found in many parts of the human
body. With respect to the preferred tissue sites of colonization of S.
dysgalactiae subsp. equisimilis, LL-37 is expressed in both respira-
tory secretions and skin (3, 33). Inhibition of the activity of LL-37
FIG 3 Schematic diagram showing the conserved repeat domain structure of DrsGL, DrsGS, DRS, and SIC AP1. For DrsGL and DrsGS, the proline-rich
sequences are found within RD2. Abbreviations: SS, signal sequence; RD1, repeat domain 1; RD2, repeat domain 2; SRR, short repeat region; PRR, proline-rich
region; LRR, long repeat region; C-term, C-terminal region.
TABLE 2 Distribution of drsGL and drsGS in S. dysgalactiae subsp.
equisimilis
emm typea
No. of drsG-
positive isolates
No. of drsG-
negative isolates DrsG variant(s)b
emm57 2 1 drsGL
stc74a 1 10 drsGL
stc839 6 3 drsGL (2), drsGS (4)
stc1400 2 12 drsGL, drsGS
stc6979 2 12 drsGS
stg6 1 12 drsGS
stg245 1 1 drsGL
stg480 2 12 drsGL, drsGS
stg485 1 3 drsGS
stg643 1 7 drsGS
stg2078 8 3 drsGS
stg3442 1 0 drsGS
stg5063 1 1 drsGL
stg62647 1 3 drsGS
a Only results for emm types with isolates possessing drsG are presented in the table.
b Numerals in parentheses represent the numbers of isolates possessing drsGS or drsGL
in the emm type specified.
FIG 4 DrsG is expressed and secreted by S. dysgalactiae subsp. equisimilis. (A)
Western blot of concentrated culture supernatants from mid-log- and station-
ary-phase cultures of drsGL-positive GGS124 (lanes 1 and 2, respectively) and
drsG-negative MD985 (lanes 3 and 4, respectively) and of recombinant DrsGL
(lane 5) probed with anti-DrsGL antibodies. (B) Western blot of concentrated
culture supernatants from mid-log- and stationary-phase cultures of drsGS-
positive MD604 (lanes 1 and 2, respectively) and drsG-negative MD128 (lanes
3 and 4, respectively) and of recombinant DrsGS (lane 5) probed with anti-
DrsGS antibodies. Molecular size markers are indicated on the left.
Smyth et al.
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would therefore be beneficial for S. dysgalactiae subsp. equisimilis
colonization at these sites. Here we demonstrated binding of DrsG
and LL-37 when DrsG was used as the bound substrate in ligand
assays. However, when the reciprocal experiment was performed,
with LL-37 as the bound substrate, no interaction was observed. A
similar result was reported by Fernie-King et al. (12) for interac-
tions between SIC and hD-2. They suggested that the difference
between the two configurations of the assay was attributable to the
masking of binding sites when a small molecule (i.e., hD-2; 64
amino acids) was bound to a plate. Given the small size of LL-37
(37 amino acids), a similar explanation could be applied. Not-
withstanding this, the biological assay showed that DrsG counter-
acted the bactericidal activity of LL-37 and provides clear support
for DrsG–LL-37 interactions.
In S. pyogenes, drs and sic are found in a restricted number of
emm types (emm12 and -55 and emm1 and -57, respectively).
Within these emm types, drs and sic are universally found in all
isolates. In contrast, we found that although drsG was present in
14 of 50 different S. dysgalactiae subsp. equisimilis emm types
tested, not all isolates from a drsG-positive emm type possessed
the gene. These results are in concordance with a recent publica-
FIG 5 DrsG does not inhibit complement-mediated lysis of erythrocytes.
Complement-mediated lysis assays were performed using DrsGL, DrsGS, SIC,
or PBS preincubated with human serum. Results are presented as % inhibition
of complement-mediated lysis, where incubation of sheep erythrocytes with
water was used as the reference point for 100% lysis. Data represent the means
for three independent experiments. Statistical significance (***) was deter-
mined using the unpaired t test.
FIG6 LL-37 interactions with DrsGL (A), DrsGS (B), and SIC (C). Graphs on the
left show the results when DrsGL, DrsGS, or SIC was used to coat the wells of a
96-well plate. LL-37 was added, followed by anti-LL-37 antibody and HRP-labeled
secondary antibody. Results for assays in which LL-37 (C1), LL-37 and primary
antibody (C2), or secondary antibody (C3) was not added are included as controls.
The graphs on the right represent the reciprocal assays, in which LL-37 was used as
the bound substrate, and free DrsGL, DrsG, or SIC was added.
FIG7 Growth of S. dysgalactiae subsp. equisimilis in the presence of LL-37 and
DrsG. S. dysgalactiae subsp. equisimilis MD985 (drsG negative) was grown in
the presence of LL-37 and/or DrsGL (A), DrsGS (B), or SIC (C). After a 2.5-h
incubation, the bacteria were recovered, plated onto Todd-Hewitt agar, and
incubated overnight. The percentage of growth compared to that of controls
was determined for each individual assay. The results presented are the means
for three independent experiments.
Characterization of drsG
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tion by Oppegaard et al. (34). When the results from this study are
combined with results from two other distribution studies (20,
34), a total of 19 S. dysgalactiae subsp. equisimilis emm types have
now been identified as possessing isolates that harbor drsG. Thus,
the distribution of drsG is widespread in S. dysgalactiae subsp.
equisimilis isolates as defined by emm type. Oppegaard et al. also
identified a third variant of DrsG. The drsGS variant from our
study corresponds to the sicG3 to -5 alleles, whereas drsGL corre-
sponds to sicG6 in their study. The smaller alleles in their study,
sicG1 and sicG2, were not found in our study. sicG1 is shorter than
both drsGS and drsGL. With the exception of the signal sequence,
the identity between the sicG1 and sicG2 alleles and all other sicG/
drsG alleles is extremely low. The mature SicG1 protein also has a
single repeat region, with no similarity to the repeat regions in
other DrsG isoforms.
The major difference between DrsGL and DrsGS is the pres-
ence of one additional repeat unit in DrsGL. Thus, within each
variant, conservation is very high both within an emm type and
across multiple emm types. In some instances, drsGS and drsGL
were present in discrete isolates of the same emm type. There are
three possible explanations for these observations. First, once a
particular isoform is acquired by an emm type, a duplication event
resulting in conversion of drsGS to drsGL or a deletion event re-
sulting in conversion of drsGL to drsGS may occur. Such recombi-
nation events may occur multiple times, giving rise to both drsGS-
positive and drsGL-positive lineages within an emm type. Second,
drsGS and drsGL may have been acquired multiple times by differ-
ent isolates of the same emm type. A third, highly improbable
hypothesis is that drsG was ubiquitously present in multiple emm
types and that, over time, deletions within the alleles (full gene or
regions within the gene) have been occurring.
Given the high degree of identity within DrsGL and DrsGS,
irrespective of emm type, the inconsistent presence of drsG within
emm types, and the fact that drsGS or drsGL can be found within
the same emm types, multiple acquisitions of drsG via lateral gene
transfer (LGT) seem the most likely explanation for the observed
distribution of drsG observed in this study. Inter- and intraspecies
LGT within the beta-hemolytic streptococci have been described
in several studies (35, 36). Whereas interspecies transfers between
GAS and S. dysgalactiae subsp. equisimilis appear to be mediated
by integrative conjugative elements (ICE) (37–39), both ICEs and
bacteriophages contribute to intraspecies LGT (40). Importantly,
many mobile genetic elements (MGEs) in GAS also carry viru-
lence genes that may alter the pathogenesis of individual strains
(41–43). Analysis of the DNA surrounding drsG in the draft
genomic sequences used in this study found drsG to be located
between scpG and SDEG_0931 (18). sic and drs are also found
adjacent to scpA in GAS. This region has previously been shown to
include MGE-associated genes in both GAS and S. dysgalactiae
subsp. equisimilis (44, 45). A gene encoding a putative transposase
was also identified between drsG and scpG in one of the draft
assemblies in this study. Since no other bacteriophage-related
genes are found in this or surrounding regions, it is likely that
nonbacteriophage MGEs are responsible for distribution of drsG
throughout the S. dysgalactiae subsp. equisimilis population.
Within the DrsGS variants, conservation at the amino acid
level is95%. Similarly high levels of amino acid conservation are
also present in DrsGL. Differences in the number of repeat units in
RD1 therefore represent the greatest level of diversity in DrsG.
Conservation of DRS has also been reported for S. pyogenes (46).
The conserved nature of DRS in the two species suggests that for
isolates that acquire this gene, it plays an important biological role.
This sequence conservation is in stark contrast to the case for sic,
where variation can be observed in epidemic waves (47), and sug-
gests that although SIC and DRS/DrsG have similar ligands, their
role in respective species may be different. Indeed, this is evident
from the wide range of ligands and functions for SIC and the
much-restricted properties of DrsG.
Proline-rich C-terminal regions are a feature of SIC and DRS.
Here we have extended this observation to DrsG. While the pro-
line-rich regions of SIC and DRS are known to bind C6, C7,
hD-2, and hD-3, the specific amino acids involved in the bind-
ing have not been elucidated. Proline-rich motifs have been iden-
tified as being important in many signaling and binding proteins
(48), and there is a growing field of research investigating the
binding capabilities and structural properties of proline-rich do-
mains. One such motif is the peptide ligand motif PxxP (where “x”
denotes any amino acid), which usually sits at the core of a pro-
line-rich domain sequence (49, 50). These domains are usually
positioned toward the ends of a protein, where they form ex-
tended structures that have been described as “sticky arms” (51).
Four such motifs are present in DrsG. Despite the limited identity,
four PxxP motifs are also found in SicG1. DRS contains four PxxP
motifs, whereas SIC contains six. The prolines involved in these
motifs are also conserved between the three proteins. Given the
relatively low identity across the rest of the molecules, it is tempt-
ing to suggest that the PxxP motif plays a critical role in the bind-
ing of LL-37.
Both commensals and pathogens have to overcome the anti-
microbial properties of AMPs if they are to successfully colonize
and persist on mucosal surfaces. Here we have shown that DrsG is
conserved and protects S. dysgalactiae subsp. equisimilis from the
antimicrobial activity of LL-37. Our results suggest that direct
inhibition of the antimicrobial activity of LL-37 is an intrinsic
property of the SIC/DRS group of proteins. Given the multifunc-
tional nature of both SIC and DRS, it is likely that DrsG inhibits
other AMPs. In doing so, we speculate that DrsG may assist S.
dysgalactiae subsp. equisimilis in colonizing and persisting in the
throat and on the skin. However, the low prevalence of drsG-
positive strains in the population suggests that the selective advan-
tages of such activity may be limited.
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